Latest news with #Oryzon
Yahoo
5 days ago
- Business
- Yahoo
High Growth Tech Stocks in Europe to Watch for Potential Expansion
The European market has shown resilience with the pan-European STOXX Europe 600 Index ending 0.65% higher, buoyed by easing trade tensions and slowing inflation in key economies, which may prompt further monetary easing by the European Central Bank. In this context of potential expansion and shifting economic policies, high-growth tech stocks become particularly intriguing for investors seeking opportunities that align with evolving market dynamics and technological advancements. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 228 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €226.34 million. Operations: Oryzon Genomics specializes in discovering and developing epigenetics-based therapeutics targeting cancer and CNS disorders. Oryzon Genomics, a trailblazer in epigenetic therapies, is making significant strides with an impressive 49.3% annual revenue growth forecast. Despite its current unprofitability, the company's strategic focus on R&D (13.26 million EUR allocated to the VANDAM project) underscores its commitment to addressing rare neurodevelopmental disorders and neuroendocrine tumors through precision medicine. The recent 15 million EUR grant for this project enhances Oryzon's potential in pioneering treatments that could revolutionize patient care in these underserved areas. Additionally, their involvement in high-profile clinical trials like the Phase I/II trial of iadademstat for small cell lung cancer further exemplifies their innovative approach within the biotech sector. With expected profitability and earnings growth of 50.17% per annum over the next three years, Oryzon is positioned to leverage its scientific advancements into commercial success. Click to explore a detailed breakdown of our findings in Oryzon Genomics' health report. Explore historical data to track Oryzon Genomics' performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Atea ASA is a leading provider of IT infrastructure and related solutions for businesses and public sector organizations across the Nordic countries and Baltic regions, with a market capitalization of NOK16.73 billion. Operations: Atea ASA generates revenue primarily from its operations in Norway, Sweden, Denmark, Finland, and the Baltics. The highest revenue contribution comes from Sweden at NOK13.06 billion, followed by Norway at NOK9 billion. Group Shared Services account for NOK10.81 billion in costs. Atea's strategic emphasis on R&D, with a notable 13% of its revenue directed towards innovation, underpins its robust position in the European tech landscape. Despite a challenging year with earnings growth contracting by 8.8%, the company's revenue is still expected to outpace the Norwegian market, growing at 9.4% annually compared to the market's 2.6%. This resilience is further highlighted by Atea's recent dividend affirmation, committing NOK 786 million back to shareholders, showcasing confidence in its financial health and ongoing value creation strategies. Dive into the specifics of Atea here with our thorough health report. Examine Atea's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Paradox Interactive AB (publ) is a company that focuses on developing and publishing strategy and management games for PC and consoles across various global regions, with a market cap of approximately SEK20.90 billion. Operations: The company generates revenue primarily from its Computer Graphics segment, amounting to SEK2.18 billion. It operates in diverse regions including North and Latin America, Europe, the Middle East, Africa, and the Asia Pacific. Paradox Interactive, amidst a dynamic European tech landscape, continues to innovate and expand its gaming universe. The company's recent announcement of two new DLC packs for "Across the Obelisk" underscores its commitment to enhancing player experience and broadening content availability across multiple platforms. Strategic alliances like the one seen with Room 8 Group for "Crusader Kings III: Legacy of Persia" not only diversify Paradox's portfolio but also deepen its historical game narratives, reinforcing its niche in strategy games. Financially, Paradox is poised for growth with a revenue increase of 9.3% annually and an earnings forecast growing at 21.5% per year, complemented by a robust R&D investment strategy that ensures continuous innovation and competitiveness in the high-stakes gaming market. Click here and access our complete health analysis report to understand the dynamics of Paradox Interactive. Gain insights into Paradox Interactive's historical performance by reviewing our past performance report. Take a closer look at our European High Growth Tech and AI Stocks list of 228 companies by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OB:ATEA and OM:PDX. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
19-03-2025
- Business
- Yahoo
High Growth Tech Stocks In Europe March 2025
In March 2025, the European market is navigating a complex landscape characterized by concerns over U.S. trade tariffs, economic growth uncertainties, and fluctuating monetary policies. Despite these challenges, high growth tech stocks in Europe continue to attract attention as investors seek opportunities that align with resilient business models and innovative capabilities capable of weathering broader market volatility. Name Revenue Growth Earnings Growth Growth Rating Elicera Therapeutics 63.53% 97.24% ★★★★★★ Pharma Mar 24.24% 40.82% ★★★★★★ CD Projekt 30.55% 39.06% ★★★★★★ Yubico 20.88% 26.53% ★★★★★★ Xbrane Biopharma 73.73% 139.21% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Devyser Diagnostics 26.50% 94.65% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Ascelia Pharma 46.09% 66.93% ★★★★★★ Skolon 29.71% 91.18% ★★★★★★ Click here to see the full list of 243 stocks from our European High Growth Tech and AI Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Oryzon Genomics S.A. is a clinical stage biopharmaceutical company focused on developing epigenetics-based therapeutics for cancer and CNS disorders, with a market cap of €228.43 million. Operations: Oryzon Genomics focuses on the discovery and development of epigenetics-based therapeutics targeting cancer and CNS disorders. As a clinical stage biopharmaceutical company, it does not currently report revenue from product sales. Oryzon Genomics is making significant strides in the biotech sector, particularly in precision medicine for psychiatric and neurodevelopmental disorders. Recently, Oryzon announced positive outcomes from Phase IIa trials of vafidemstat in various psychiatric conditions and is advancing this promising drug into a Phase III trial for Borderline Personality Disorder, with FDA discussions set for the first half of 2025. This progression underscores Oryzon's commitment to addressing unmet medical needs through innovative therapies. Furthermore, the company's recent presentation at BIO-Europe Spring and its continuous R&D efforts highlight its potential to impact future treatments significantly. With an annual revenue growth forecast at 52% and earnings expected to surge by approximately 54%, Oryzon exemplifies a dynamic player within Europe's high-growth tech landscape. Navigate through the intricacies of Oryzon Genomics with our comprehensive health report here. Gain insights into Oryzon Genomics' past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: BioGaia AB (publ) is a healthcare company that develops and sells probiotic products globally, with a market capitalization of SEK11.83 billion. Operations: The company generates revenue primarily from its Pediatrics segment, contributing SEK 1.09 billion, followed by the Adult Health segment at SEK 321.29 million. BioGaia, a Swedish biotech firm, has recently demonstrated robust financial performance with its Q4 sales surging by 23% to SEK 365 million and operating profit increasing by 28% to SEK 103 million. This growth is underpinned by an annual revenue increase of 10.9% and earnings growth forecasted at 15% per year, outpacing the Swedish market averages significantly. The company's strategic move to directly manage its operations in France reflects a proactive approach in tapping into the growing health-conscious consumer base there, leveraging its reputation for high-quality probiotics. These developments suggest BioGaia is effectively capitalizing on niche market trends while maintaining strong financial health. Click here to discover the nuances of BioGaia with our detailed analytical health report. Assess BioGaia's past performance with our detailed historical performance reports. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Telefonaktiebolaget LM Ericsson (publ) is a company that offers mobile connectivity solutions to communications service providers, enterprises, and the public sector, with a market capitalization of approximately SEK278.13 billion. Operations: Ericsson generates revenue primarily from its Networks segment, which accounts for SEK158.21 billion, followed by Cloud Software and Services at SEK62.64 billion, and Enterprise at SEK24.86 billion. The company's business model focuses on providing mobile connectivity solutions to various sectors including communications service providers and enterprises. Telefonaktiebolaget LM Ericsson, a stalwart in telecommunications, is making significant strides in leveraging advanced technologies like AI and 5G. With its recent strategic alliances, including a notable partnership with Volvo Group and Bharti Airtel to explore Extended Reality and Digital Twin technologies, Ericsson is at the forefront of industrial digital transformation. This collaboration aims to enhance manufacturing processes and workforce training through the integration of 5G's ultra-low latency capabilities. Financially, Ericsson has demonstrated robust growth with a notable increase in earnings forecasted at an impressive 47% annually. Despite moderate revenue growth projections at 1.9% per year, the company's commitment to R&D remains strong, ensuring sustained innovation and competitiveness in the high-tech industry landscape. Dive into the specifics of Telefonaktiebolaget LM Ericsson here with our thorough health report. Review our historical performance report to gain insights into Telefonaktiebolaget LM Ericsson's's past performance. Click here to access our complete index of 243 European High Growth Tech and AI Stocks. Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance. Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BME:ORY OM:BIOG B and OM:ERIC B. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
03-03-2025
- Business
- Yahoo
Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
Leading US psychiatric experts join Oryzon's Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and key secondary endpoints for Phase III trial, aligned with FDA standards Oryzon moves forward with plans to submit Phase III protocol to the FDA in 1H 2025 MADRID and CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has established the primary and key secondary endpoints for its planned Phase III clinical trial evaluating vafidemstat in Borderline Personality Disorder (BPD). This milestone was reached in collaboration with Oryzon's newly formed Clinical Advisory Board (CAB), composed of leading experts in psychiatry research and clinical trials for psychiatric disorders. The CAB's insights have been instrumental in ensuring that the Phase III protocol aligns with FDA expectations and incorporates well-validated, widely recognized assessment scales to measure agitation and aggression in BPD patients. This development follows the successful completion of the Phase IIb PORTICO trial, which received positive feedback from the FDA, and positions Oryzon to submit the Phase III protocol for regulatory review in the first half of 2025. 'We are honored to collaborate with such a distinguished panel of experts as we advance vafidemstat into Phase III development,' said Dr. Carlos Buesa, Chief Executive Officer of Oryzon. 'Their expertise in psychiatric disorders and clinical trial methodology strengthens our program and ensures that we are well-prepared for the next regulatory interactions. Addressing aggression and agitation in BPD remains an urgent medical need, and we are committed to delivering innovative solutions for these patients.' Oryzon's Clinical Advisory Board Members: Oryzon's CAB includes internationally recognized leaders in psychiatry and clinical trial research: Dr. Alan F. Schatzberg, Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences at , former Chair of the Department (1991–2010), and current Director of the Stanford Mood Disorders Center. A past President of the American Psychiatric Association (2009–2010), he is a leading expert in mood disorders, particularly the neurobiology and treatment of depression. Dr. Eric Hollander, Professor of Psychiatry and Director of the Autism and Obsessive Compulsive Spectrum Program at , is a leading authority on obsessive-compulsive and related disorders. He has received multiple NIMH grants to develop treatments for BPD, with a research focus on the neurobiology of aggression and affective instability in BPD. Dr. Sarah Fineberg, Assistant Professor of Psychiatry at , specializes in the neurobiology of BPD. Her research explores social cognition and decision-making using computational psychiatry and neuroimaging. She has led clinical trials testing novel interventions for BPD, including sub-anesthetic ketamine for BPD and real-time fMRI neurofeedback. Dr. Emil F. Coccaro, George T. Harding III, M.D., Endowed Professor in the Department of Psychiatry and Behavioral Health at , is a leading expert in the neurobiology of aggression and impulsivity. His work has significantly advanced the understanding and treatment of impulsive aggression in BPD through pharmacological interventions. 'These are the right experts to help us shape a Phase III program that is both scientifically rigorous and clinically meaningful,' added Dr. Buesa. 'It is particularly reassuring that their expert medical opinion and years of practice recognize aggression as one of the most debilitating aspects of many psychiatric disorders, and particularly in borderline personality disorder. Their contributions have been instrumental in defining the primary and secondary endpoints, that will generate robust data for regulatory submissions.' Next Steps in Vafidemstat's Development Oryzon remains committed to progressing vafidemstat as a potential first-in-class treatment for agitation and aggression in BPD. Following the FDA's feedback on the PORTICO trial results, Oryzon plans to submit the Phase III protocol in the first half of 2025, with trial initiation expected soon after, pending regulatory approval and securing the necessary funding. Beyond BPD, vafidemstat is being evaluated in a Phase IIb trial for the treatment of negative symptoms in schizophrenia (EVOLUTION trial) and is part of Oryzon's broader CNS precision medicine approach. The company is also exploring additional applications in genetically defined subpopulations and neurodevelopmental disorders. For more information about the experience of the CAB members, please visit the CAB section in our website, here. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit About Vafidemstat Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor. The molecule acts on several levels: it reduces cognitive impairment, including memory loss and neuroinflammation, and at the same time has neuroprotective effects. In animal studies vafidemstat not only restores memory but reduces the exacerbated aggressiveness of SAMP8 mice, a model for accelerated aging and Alzheimer's disease (AD), to normal levels and also reduces social avoidance and enhances sociability in murine models. In addition, vafidemstat exhibits fast, strong, and durable efficacy in several preclinical models of multiple sclerosis (MS). Oryzon has performed two Phase IIa clinical trials in aggressiveness in patients with different psychiatric disorders (REIMAGINE, see Ferrer et al, Psychiatry & Clin Neurosci, 2025, and in aggressive/agitated patients with moderate or severe AD (REIMAGINE-AD), with positive clinical results reported in both. Additional finalized Phase IIa clinical trials with vafidemstat include the ETHERAL trial in patients with Mild to Moderate AD, where a significant reduction of the inflammatory biomarker YKL40 was observed after 6 and 12 months of treatment, and the pilot, small-scale SATEEN trial in Relapse-Remitting and Secondary Progressive MS, where anti-inflammatory activity was also observed. Vafidemstat has also been tested in a Phase II in severe Covid-19 patients (ESCAPE) assessing the capability of the drug to prevent ARDS, one of the most severe complications of the viral infection, where it showed significant anti-inflammatory effects in severe Covid-19 patients. Vafidemstat is currently advancing as a Phase III-ready asset in Borderline Personality disorder (BPD) following completion of the global, randomized, double blind Phase IIb PORTICO trial (final data presented at ECNP-2024). Following receipt of the minutes from the End-of-Phase II meeting with the FDA to discuss PORTICO's results, the company announced plans to move forward with a Phase III PORTICO-2 trial in agitation/aggression in BPD (FDA submission planned in 1H2025). Vafidemstat is also being investigated in a double-blind, randomized, placebo-controlled Phase IIb trial in negative symptoms of schizophrenia (EVOLUTION trial, recruitment ongoing). The company is also deploying a CNS precision medicine approach with vafidemstat in genetically-defined patient subpopulations of certain CNS disorders and is evaluating a clinical trial in Kabuki Syndrome patients. The company is also exploring the clinical development of vafidemstat in other neurodevelopmental syndromes. FORWARD-LOOKING STATEMENTSThis communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@ Sign in to access your portfolio
Yahoo
28-02-2025
- Business
- Yahoo
ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
All resolutions were approved MADRID, Spain and CAMBRIDGE, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A., a clinical-stage biopharmaceutical company focused on epigenetics for the development of therapies for diseases with significant unmet medical needs, today announced the results of voting at the Extraordinary General Shareholders' Meeting held today in Madrid. A total of 24,030,812 of the Company's issued and outstanding ordinary shares (representing 36.5312% of the share capital) were at the Meeting, either in person or represented by proxy. The Company's shareholders approved all of the resolutions listed below, proposed by the Board of Directors at the Company's Extraordinary General Meeting, with favorable votes ranging from 94% to 97%. Appointment and re-election of directors. Re-election of Mr. Carlos Buesa as executive director. Re-election of Mr. Manuel López-Figueroa as independent director. Appointment of Mr. Konstantinos Alataris as independent director. Appointment of Mr. Luis Sánchez Quintana as independent director. Appointment of Ms. Montserrat Vendrell as independent director. Appointment of Mr. Pierre Beaurang as independent director. Approval of the issuance of convertible bonds, excluding the pre-emptive subscription right, under the investment agreement entered into with Nice & Green, S.A., on November 20, 2023. Authorization to the Board of Directors to increase the share capital under the terms of Article 297.1.b) of the Spanish Companies Act. Delegation for the exclusion of pre-emptive subscription rights in accordance with the provisions of Article 506 of the Spanish Companies Act. Delegation to the Board of Directors of the power to issue fixed income securities, preferred participations or instruments of a similar nature (including promissory notes or warrants) convertible and/or exchangeable into shares of the Company. Establishment of criteria for the determination of the bases and modalities of the conversion and/or exchange and attribution to the Board of Directors of the powers to increase the capital by the necessary amount, as well as to exclude the preemptive subscription rights of the shareholders and holders of convertible securities. Authorization to the Board of Directors for the acquisition of own shares, directly or, as the case may be, through companies dependent on the Company. Delegation of powers for the formalization, correction, registration, interpretation, development and execution of the resolutions adopted by the General Shareholders' Meeting. The complete details of the resolutions that have been approved in their entirety and the results of the votes by separate items will be available on the Company's website in the near future. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon's team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates' and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@ mcordera@ etorrell@ svonderweid@ Sign in to access your portfolio
